Abstract:7 Objectives: Negative allosteric modulation of metabotropic glutamate receptor 2 (mGlu2) represents a novel specific and selective approach for treating brain disorders. Positron emission tomography (PET) imaging of mGlu2 would facilitate disease diagnosis and negative allosteric modulators (NAMs) discovery. However, few efforts have been disclosed to visualize mGlu2in vivo, indicating an unmet and urgent clinical demand. Herein we report the proof-of-concept development of PET tracers derived from NAMs for successfully imaging of mGlu2. Methods: A library seven mGlu2 NAMs 1a-1g were synthesized and subjected to the investigation of pharmacological and physicochemical properties. As a result, 1a and 1b showed excellent potency and selectivity, and then radiolabeled with 11C. The specificities of both PET tracers [11C]1a and [11C]1b were validated by in vitro autoradiography (ARG) with rat brain slices. Dynamic PET imaging were performed on normal Sprague-Dawley (SD) rats to assess the capability for brain penetration and in vivo specificity by the simplified reference tissue model (SRTM) with the pons as the reference region. Whole body biodistribution and metabolite studies were conducted in rodents to evaluate the pharmacokinetic properties of [11C]1b. Results: All of the novel compounds were synthesized in five steps with 14-20% overall yields.1a and 1b showed good binding potency (IC50 to mGlu2 30 μM), together with reasonable lipophilicity and tPSA. 11C radiolabeling were conducted within 40 min on GE TracerLab FXC, and radiochemical yields were 36.6 ± 7.3% (n = 7, [11C]1a) and 6.53 ± 1.5% (n = 10, [11C]1b) respectively, with high radiochemical purities and molar activities. ARG results showed that [11C]1b was much more specific to mGlu2 with highest radioactivity accumulated in the striatum and cerebral cortex, followed by hippocampus and cerebellum. The heterogeneous distribution was diminished by pre-incubation with the corresponding standard compounds or QCA. The non-displaceable binding potential (BPND) of [11C]1bwere calculated by PET, and the highest values were observed in striatum and cingulate cortex (0.72), followed by cerebral cortex (0.42) and hippocampus (0.48), and the lowest BPND was identified in the cerebellum (0.12) under baseline conditions. The BPND values were decreased substantially by pretreatment with 1b (41-88% reduction, 1 mg/kg) or 1a (48-90% reduction, 3 mg/kg). Biodistribution studies of [11C]1b demonstrated that high brain uptake (ca. 3.6 %ID/g) was detected after 5 min post injection, which was consistent with PET imaging data. Several peripheral organs with high mGlu2 expression were also observed with high radioactivity accumulation. Notably, metabolite analysis suggested that [11C]1bshowed excellent in vivo stability in brain with more than 99% unchanged fraction at 20 min post injection. Conclusion: We have developed [11C]1b as a potent and promising PET tracer for neuroimaging of mGlu2. Translational PET imaging in nonhuman primates are on the way and will be reported in due course.

Synthesis of [11C]BIIB104, an α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic-Acid-Positive Allosteric Modulator, and Evaluation of the Bio-Distribution in Non-Human Primate Brains Using Positron Emission Tomography

Synthesis, pharmacology and preclinical evaluation of 11C-labeled 1,3-dihydro-2H-benzo[d]imidazole-2-ones for imaging γ8-dependent transmembrane AMPA receptor regulatory protein

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

Synthesis And Initial In Vivo Studies With [C-11]Sb-216763: The First Radio Labeled Brain Penetrative Inhibitor Of Gsk-3

Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.

Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP)

Preclinical in vitro and in vivo evaluation of [11C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors

Preclinical Evaluation Of Radiolabeled Negative Allosteric Modulators For Pet Imaging Of Metabotropic Glutamate Receptor 2

Radiosynthesis automation, non-human primate biodistribution and dosimetry of K+ channel tracer [11C]3MeO4AP

AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer

Comparison of Two Pde10a Radiotracers, [11c]tz1964b and [18f]mni659 in the Brains of Non-Human Primates

First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.

A radioligand for in vitro autoradiography of CSF1R in post-mortem CNS tissues

Synthesis and preclinical evaluation of <SUP>11</SUP>C-labeled (6-aryl-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)acetamide for imaging GluN2B subunit of NMDA receptors

C-11-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors

Radiosynthesis and ex vivo evaluation of [11C]-SIB-1553A as a PET radiotracer for beta4 selective subtype nicotinic acetylcholine receptor

Radiolabel uncovers nonintuitive metabolites of AMPAR potentiator BIIB104: Novel release of [ 14 C]cyanide from 2-cyanothiophene and subsequent formation of [ 14 C]thiocyanate

Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2

Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies

Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain